HHS OIG To Probe Hospital Use Of 503B Compounded Sterile Drugs

HHS' Office of Inspector General plans to investigate how 503B outsourcing facilities and hospitals produce and use compounded sterile drugs and how many of them voluntarily register with FDA. The study, part of the OIG's work plan for fiscal 2017, is a check in to see whether the nascent outsourcing facility sector is working as intended, according to the International Academy of Compounding Pharmacists (IACP) and The Pew Charitable Trusts. "OIG's examination of the purchasing patterns of hospitals may provide...